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MRC-5 cells are used for vaccine production, including varicella zoster virus, MMR, polio, rotavirus, rabies, 
hepatitis A, and dengue virus. As human diploid fibroblast cells, MRC-5 can be passaged for about 42-48 
population doublings before they become senescent. Vaccine manufacturers generally culture diploid cells in 
classical medium with 10% serum. Due to the limited population doublings, there is a short window for 
adaptation to serum-free medium and successful scale-up for vaccine production. Here, we report the 
development of a serum-free medium for MRC-5 cells that allows for direct adaptation and reaches comparable 
doubling times and virus titers as serum-containing medium. Using metabolite analysis and a design of 
experiment rationale, we developed a serum-free medium for growth of MRC-5 cells that can support direct 
recovery from thaw and adaptation-free expansion, while resulting in performance that is comparable to serum-
containing medium. Since requirements for production of viruses are different from cell growth, we optimized the 
production medium separately. With the animal-origin-free production medium, manufacturers can produce 
vaccines without concern about the bovine serum albumin limit of 50ng/dose as set by the WHO. We confirmed 
virus production with varicella zoster virus and vesicular stomatitis virus (as an analog to rabies virus) and 
demonstrate titers that are up to one log higher than classical medium control. Taken together, we have 
developed a serum-free medium for MRC-5 cells that supports growth and virus production. By switching to a 
serum-free process, vaccine manufacturers can reduce dependency on serum, production and purification 
costs, and increase product consistency and safety. 
   
 
